Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Terns Pharmaceuticals, Inc.
< Previous
1
2
Next >
Terns Pharmaceuticals Appoints Heather Turner, J.D., to Board of Directors
November 18, 2024
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TERN
Terns Pharmaceuticals Reports Third Quarter 2024 Financial Results and Corporate Updates
November 12, 2024
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TERN
Terns Pharmaceuticals to Participate in Upcoming November Investor Conferences
November 06, 2024
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TERN
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
October 07, 2024
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TERN
Terns Announces Closing of Public Offering of Shares of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
September 12, 2024
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TERN
Terns Announces Pricing of Upsized $150.15 Million Public Offering
September 10, 2024
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TERN
Terns Announces Proposed Public Offering
September 09, 2024
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TERN
Terns Pharmaceuticals Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity
September 09, 2024
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TERN
Terns Pharmaceuticals Reports Second Quarter 2024 Financial Results and Corporate Updates
August 05, 2024
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TERN
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
August 01, 2024
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TERN
Terns Pharmaceuticals Appoints Biotech Executive Elona Kogan as Chief Legal Officer and Announces Upcoming CFO Transition
July 29, 2024
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TERN
Terns Pharmaceuticals Highlights New Preclinical Data Supporting TERN-501 in Combination with a GLP-1R Agonist for Obesity at the ADA’s 84th Annual Scientific Sessions and Upcoming Conference Participation
June 21, 2024
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TERN
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
June 03, 2024
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TERN
Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences
May 30, 2024
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TERN
Terns Pharmaceuticals to Participate in UBS Obesity Therapeutics Day
May 17, 2024
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TERN
Terns Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Updates
May 13, 2024
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TERN
Terns Pharmaceuticals Announces Leadership Changes
May 08, 2024
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TERN
Terns Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference 2024
May 07, 2024
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TERN
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
May 03, 2024
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TERN
Terns Pharmaceuticals Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor TERN-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation
April 29, 2024
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TERN
Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer
April 10, 2024
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TERN
Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
March 14, 2024
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TERN
Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemia
March 11, 2024
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TERN
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
March 07, 2024
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TERN
Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences
February 27, 2024
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TERN
Terns Pharmaceuticals Reports Inducement Grants to New Chief Executive Officer Under Nasdaq Listing Rule 5635(C)(4)
February 07, 2024
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TERN
Terns Pharmaceuticals Appoints Amy Burroughs as Chief Executive Officer
February 07, 2024
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TERN
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
February 02, 2024
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TERN
Terns Pharmaceuticals to Highlight 2024 Priorities and Clinical Milestones at the 42nd Annual J.P. Morgan Healthcare Conference
January 04, 2024
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TERN
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
January 03, 2024
From
Terns Pharmaceuticals, Inc.
Via
GlobeNewswire
Tickers
TERN
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.